Stock JENBURPH6 JENBURKT PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Jenburkt Pharmaceuticals Limited

Equities

JENBURPH6

INE354A01013

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:01:01 2024-07-05 EDT 		5-day change 1st Jan Change
877.6 INR -0.10% Intraday chart for Jenburkt Pharmaceuticals Limited +0.59% +29.02%
05-28 Jenburkt Pharmaceuticals Limited Announces Board Retirements CI
05-28 Jenburkt Pharmaceuticals Limited Announces Dividend CI

Valuation

Fiscal Period: März 2019 2020 2021 2022 2023 2024
Capitalization 1 2,319 1,459 1,828 2,601 2,939 3,043
Enterprise Value (EV) 1 1,870 965 1,359 2,202 2,474 2,303
P/E ratio 11.7 x 9.81 x 11.1 x 11.7 x 11.9 x 11.7 x
Yield 2.02% 2.55% 2.56% 2.12% 2.16% 2.22%
Capitalization / Revenue 1.89 x 1.23 x 1.67 x 2.1 x 2.15 x 2.14 x
EV / Revenue 1.52 x 0.81 x 1.24 x 1.78 x 1.81 x 1.62 x
EV / EBITDA 7.49 x 5.16 x 7.13 x 8.24 x 8.28 x 7.1 x
EV / FCF 62.4 x 8.37 x 8.16 x 15.4 x 18.9 x 12.6 x
FCF Yield 1.6% 11.9% 12.3% 6.51% 5.3% 7.93%
Price to Book 2.99 x 1.82 x 1.86 x 2.22 x 2.4 x 2.1 x
Nbr of stocks (in thousands) 4,589 4,589 4,589 4,589 4,413 4,413
Reference price 2 505.2 317.8 398.4 566.6 666.0 689.4
Announcement Date 19-06-24 20-08-04 21-08-01 22-07-02 23-06-30 24-07-02
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: März 2019 2020 2021 2022 2023 2024
Net sales 1 1,226 1,189 1,093 1,240 1,367 1,420
EBITDA 1 249.6 187 190.5 267.1 298.9 324.2
EBIT 1 236.2 174.5 178.1 254.4 281.9 307.8
Operating Margin 19.26% 14.67% 16.29% 20.52% 20.61% 21.68%
Earnings before Tax (EBT) 1 266.3 211.4 216.4 298.7 328.6 351.8
Net income 1 198 148.7 165 223 246.1 259.8
Net margin 16.14% 12.51% 15.1% 17.98% 17.99% 18.3%
EPS 2 43.14 32.40 35.96 48.58 55.76 58.86
Free Cash Flow 1 29.98 115.2 166.5 143.3 131.2 182.7
FCF margin 2.44% 9.69% 15.24% 11.56% 9.59% 12.87%
FCF Conversion (EBITDA) 12.01% 61.62% 87.43% 53.66% 43.88% 56.36%
FCF Conversion (Net income) 15.14% 77.5% 100.92% 64.29% 53.3% 70.34%
Dividend per Share 2 10.20 8.100 10.20 12.00 14.40 15.30
Announcement Date 19-06-24 20-08-04 21-08-01 22-07-02 23-06-30 24-07-02
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: März 2019 2020 2021 2022 2023 2024
Net Debt 1 - - - - - -
Net Cash position 1 449 494 469 398 466 740
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 30 115 167 143 131 183
ROE (net income / shareholders' equity) 28.5% 18.9% 18.5% 20.7% 20.5% 19.4%
ROA (Net income/ Total Assets) 16.4% 10.5% 9.91% 12% 12.4% 12.5%
Assets 1 1,209 1,411 1,666 1,852 1,989 2,072
Book Value Per Share 2 169.0 174.0 215.0 256.0 277.0 328.0
Cash Flow per Share 2 2.670 5.520 5.430 11.00 8.290 9.350
Capex 1 24 45.5 11.5 30.5 21 25.5
Capex / Sales 1.96% 3.83% 1.05% 2.46% 1.54% 1.8%
Announcement Date 19-06-24 20-08-04 21-08-01 22-07-02 23-06-30 24-07-02
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
JENBURKT PHARMACEUTICALS LIMITED Stock Jenburkt Pharmaceuticals Limited
+29.02% 46.39M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+56.89% 823B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+39.52% 627B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.55% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.99% 320B
ABBVIE INC. Stock AbbVie Inc.
+7.92% 295B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.74% 239B
NOVARTIS AG Stock Novartis AG
+13.83% 220B
ROCHE HOLDING AG Stock Roche Holding AG
-0.49% 219B
AMGEN INC. Stock Amgen Inc.
+7.94% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. JENBURPH6 Stock
  4. Financials Jenburkt Pharmaceuticals Limited